Premium
Harmlessness of 1 mg cefuroxime intracameral injection at the end of cataract surgery
Author(s) -
BARREAU G,
BOURMAULT L,
DOST L,
ADENIS JP,
ROBERT PY
Publication year - 2013
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2013.4452.x
Subject(s) - medicine , cefuroxime , ophthalmology , cataract surgery , surgery , macular degeneration , antibiotics , microbiology and biotechnology , biology
Purpose Intracameral 1mg cefuroxime injection at the end of cataract surgery is included in the good practice in France and a lot of countries. Few studies have shown a macular toxicity for high doses of cefuroxime in particular in a case of dilution error for exemple. Methods We propose a study on 18, of simple cataract operated, eyes : by phakoemulsification, the same surgeon, without particular surgical complications, and no posterior capsule rupture. Only patients with medium cataract and a normal macula were included in the study. A time‐domain macular OCT was pre‐operatively made, and then at 7 and 30 post‐operative days. The principal criterion of judgement was the central macular thickness at 30 post‐operative days. Results The average pre‐operative central macular thickness was 209,11 +/‐ 29,44 microns (143‐279), at 7 post‐operative days the average was 214,44 +/‐ 28,42 microns (145‐267), and at 30 post‐operative days was 219,44 +/‐ 27,41 microns (145‐253). The differences observed between the pre and post‐operative values were not significant. Conclusion These results show that at a dose of 1 mg, as an intracameral injection, and without posterior capsular rupture, cefuroxime does not significativly increase the central macular thickness. A study with a larger pool of patients would certainly confirm what the actual clinical practice lets us foresee.